Effect of Sekanjabin e Safarjali (Quince Oxymel) in the Prevention of Migraine Attacks

Comparison of Effectiveness of Sekanjabin e Safarjali (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02179775

Enrollment

Registered

2014-07-02

Start date

2014-07-31

Completion date

2014-10-31

Last updated

2014-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Diseases, Migraine Headache

Brief summary

The purpose of this study is to determine whether Quince Oxymel is effective in the prevention of Migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.

Detailed description

This is a randomized, placebo-controlled, triple blinded clinical study to evaluate the effects of oral use of Sekanjebin e Safarjali (Quince Oxymel) in the Prevention of Migraine attacks in patients with simultaneous upper gastrointestinal dysfunction.45 patients with Migraine headache aged between 15-70, after taking signed informed consent, according to the International headache society criteria for headache \[2\] are included in this trial. 45 cases with Migraine headache with simultaneous upper gastrointestinal dysfunction will allocate to three arms by using simple randomization. Quince Oxymel, propranolol and placebo will be given as encoded, innominate bottles with the same shape and color. Quince oxymel and placebo will be prescribed as 10 cc, three times a day for 4 weeks. Frequency, duration and intensity of Migraine Attacks at the beginning time and during 4 weeks of trial, will be evaluated, as the primary outcome measures.

Interventions

DRUGpropranolol

DRUGQuince's oxymel

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* minimum age of 18 years old * giving a written informed consent * having at least 2 migraine attacks per month

Exclusion criteria

* patients older than 70 years old * patients with Diabetes mellitus * patients with chronic obstructive pulmonary disease and asthma * pregnancy * severe depression * patients affected by sexual disorders * bradyarrhythmic patients * positive history of hypersensitivity reactions to quince, ginger, propranolol or naproxen

Design outcomes

Primary

Measure	Time frame
duration of headache attacks	4 weeks
Pain Scores as assessed by the Visual Analog Scale	4 weeks
frequency of headache attacks	4 weeks

Secondary

Measure	Time frame
self-reported improvement of upper gastrointestinal symptoms (by percent)	4 weeks

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026